UNRESECTABLE RENAL CELL CARCINOMA
Clinical trials for UNRESECTABLE RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gut bacteria boosts cancer therapy? new combo trial for kidney cancer
Disease control OngoingThis early-phase study tests whether adding a gut bacteria supplement (CBM588) to standard cancer drugs (nivolumab and cabozantinib) can improve treatment for advanced kidney cancer. About 31 adults with metastatic kidney cancer will take the supplement alongside their regular th…
Matched conditions: UNRESECTABLE RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for rare kidney cancer: drug combo shows promise
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system attack cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes …
Matched conditions: UNRESECTABLE RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New immune cell therapy targets five Hard-to-Treat cancers
Disease control TerminatedThis early-stage trial was designed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells (T cells) taken fro…
Matched conditions: UNRESECTABLE RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Fasting to fight cancer: study tests eating windows for better immunotherapy results
Knowledge-focused TerminatedThis study aimed to see if limiting eating to a 10-hour window each day could improve how well immunotherapy works in people with advanced head and neck or kidney cancer. Researchers wanted to know if this eating pattern changes gut bacteria and boosts treatment response. The stu…
Matched conditions: UNRESECTABLE RENAL CELL CARCINOMA
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated May 17, 2026 10:08 UTC